Anzeige
❌
Mehr »
Samstag, 03.10.2026 - Börsentäglich über 12.000 News
Die Lizenz, über die niemand spricht, und warum Wettbewerber keine bekommen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 936386 | ISIN: US8006771062 | Ticker-Symbol: GBY
Lang & Schwarz
03.10.26 | 09:00
0,126 Euro
-100,00 % -0,126
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SANGAMO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SANGAMO THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0970,15509:00

Aktuelle News zur SANGAMO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.09.SANGAMO THERAPEUTICS, INC - 8-K, Current Report10
08.09.SANGAMO THERAPEUTICS, INC - 8-K, Current Report7
17.08.SANGAMO THERAPEUTICS, INC - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB27
13.08.PTC Therapeutics' $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy10
SANGAMO THERAPEUTICS Aktie jetzt für 0€ handeln
13.08.PTC takes a chance on Sangamo's Fabry disease gene therapy4
13.08.Lilly, PTC Therapeutics snap up bankrupt Sangamo's main assets12
13.08.PTC to Acquire Sangamo's Fabry Disease Gene Therapy12
13.08.PTC's $211M bid wins Sangamo auction, teeing up 'special opportunity' to enter Fabry market3
12.08.PTC acquiring Fabry disease gene therapy from Sangamo in up to $211M deal3
12.08.Sangamo Therapeutics, Inc.: Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones466PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed...
► Artikel lesen
20.07.SANGAMO THERAPEUTICS, INC - 8-K, Current Report59
01.07.SANGAMO THERAPEUTICS, INC - 8-K, Current Report28
24.06.Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor51
23.06.Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle21
23.06.Sangamo to put 'substantially all' assets for sale in bankruptcy, lines up Lilly and Astellas as buyers7
23.06.Sangamo Announces Asset Sale Agreements; Commences Chapter 11 Proceedings923INDIANAPOLIS (dpa-AFX) - Sangamo Therapeutics has entered into two separate asset sale agreements, one with Eli Lilly and Company (LLY) for Sangamos capsid delivery platform, zinc finger platform...
► Artikel lesen
23.06.SANGAMO THERAPEUTICS, INC - 8-K, Current Report8
23.06.Sangamo files for Chapter 11, signs asset sale deals with Lilly6
23.06.Sangamo meldet Insolvenz nach Chapter 11 an und verkauft Sparten an Eli Lilly50
23.06.Sangamo Therapeutics, Inc.: Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas1.779Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders Lilly and Astellas to serve as "stalking...
► Artikel lesen
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,13